| 5 min read
From advances in graft versus host disease treatment to updates on H5N1 and Duchenne muscular dystrophy research, the DDN editors break down the news this week.
| 3 min read
Unlike in other brain regions, levels of the neurotransmitter decrease in the cerebellum when anxiety is high, suggesting a potential new drug target.
| 8 min read
Virus-inspired delivery methods enable gene editing of dysregulated microbes.News
| 3 min read
Vertex Pharmaceuticals’ drug, Journavx, blocks a sodium channel outside of the brain. Experts hope that this non-addictive pain drug may be the first of many.
| 6 min read
Judy Sebolt-Leopold and her team at MEKanistic Therapeutics developed a single molecule targeting two kinase enzymes that drive resistance to cancer therapies.
| 4 min read
DDN editors break down a surprising connection between microplastics and antimicrobial resistance, vitamin D for multiple sclerosis, obesity drugs updates, and more news from this week.
| 3 min read
An enzyme reconstructed from a three-billion-year-old bacterium widens gene editing capabilities to even more regions of the genome.
| 7 min read
Most cancer cells have the wrong number of chromosomes, known as aneuploidy. Scientists are finding ways to target this flaw with new treatments.
| 5 min read
Michelle Werner and her team at Alltrna are developing novel tRNA therapeutics to overwrite mutations shared by hundreds of rare genetic diseases.
| 10+ min read
GLP-1 agonists have transformed the treatment of type 2 diabetes and obesity, but they come with side effects. Physicians say the benefits outweigh the risks.
| 6 min read
Sabrina Johnson at Daré Bioscience is redefining contraception with Ovaprene, a non-hormonal, monthly option for safe and effective birth control.
| 4 min read
People and mice with ALS-linked mutations show altered sleep patterns early in life. Modifying sleep hormone levels normalized sleep cycles in mice.
| 2 min read
New animal research suggests that the risk of developing cancer might be decided early in life.
| 3 min read
A close encounter with a venomous critter sparked insight for communicating science in times of stress.
| 2 min read
Researchers revealed for the first time that CAR T cells can transfer their CAR molecules to regular T cells in a process known as trogocytosis.
| 3 min read
Levels of neuroactive steroids during the third trimester of pregnancy may indicate postpartum depression risk.
| 4 min read
Targeting a gut bacterial species or its metabolites could potentially improve diabetes management by reducing sugar preferences.
| 8 min read
Lundbeck Therapeutics is testing a monoclonal antibody that targets a novel neuropeptide in a Phase 2b clinical trial.
| 4 min read
As a CD40 ligand antagonist, dazodalibep blocks immune cell communication, potentially serving as the first drug to target the autoimmune disease’s cause.
| 4 min read
A strain of E. coli linked to Crohn’s disease produces a compound that triggers intestinal scarring, revealing a potential treatment path.
Page 1 of 28 - 542 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Harnessing liver-on-a-chip models for drug safety
Discover how researchers leverage microphysiological systems in toxicology studies.
Enhancing bioanalytical studies with centralized data management
Learn how researchers can improve compliance and efficiency with advanced LIMS solutions.
Explained: How are metabolite biomarkers improving drug discovery and development?
By offering a rich source of insights into disease and drugs, metabolite biomarkers are at the forefront of therapeutic exploration.
